Weight Loss

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive...

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering...

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY). Layoffs are also under consideration as part of broader cost-cutting...

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy. HIMS is taking a hit from negative sentiment. See...

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill. Participants receiving once-daily doses of oral VK2735 demonstrated a mean body weight reduction of up to 12.2% after 13 weeks from baseline. Participants receiving...

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies. Novo Nordisk is leading the...

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes Ozempic the first once-weekly treatment for type 2 diabetes that not only improves glycemic control but...

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in oral and...

Vacations are on hold, dinners out skipped, and doses stretched — all so patients can keep taking weight-loss drugs like Wegovy and Zepbound as insurers pull back coverage in 2025. Physicians say insurance coverage is more limited this year, according to Reuters. As a result, many employers are...

A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients. The initiative, announced Tuesday, combines government and private sector funding to expand holistic care through community, pharmacy, and digital...

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist. For the primary endpoint, orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2....

Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's proprietary NanoPortal implant technology. Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand...

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY)...

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003. Read more about the NVO stock price here....

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH),...